Clinical Trial News Archive
Get news by email or subscribe to our news feeds.
News Archive for November 2009
November 2, 2009
- Alnylam Presents New Pre-Clinical Data on ALN-TTR, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis
- Avila Presents Data on Its Novel, Orally-Available Protease Inhibitor, AVL-181, Demonstrating Viral Clearance of Hepatitis C Virus in Preclinical Models
- Salix Pharmaceuticals Reviews American Association for the Study of Liver Diseases Annual Meeting
- Dynavax's HEPLISAV Shows Increased Protection Rate for Chronic Kidney Disease Patients
- Results from two Canadian studies confirm sustained viral response rates seen in hepatitis C patients treated with Pegatron
- Novobiotics - Positive Initial Phase IIa Data
- GlobeImmune's Hepatitis C Therapeutic Vaccine Combined with Standard of Care Increases End of Treatment Response Rate by 15%
- Genta Announces Top-Line Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced Melanoma
- Æterna Zentaris Announces Positive Preliminary Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Ovarian Cancer
- Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
- Human Genome Sciences and GlaxoSmithKline Announce Positive Results in Second of Two Phase 3 Trials of Benlysta in Systemic Lupus Erythematosus
- Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting
- Large Study of Anemia Treatment in Chronic Kidney Disease Patients Not on Dialysis Published in the New England Journal of Medicine Failed to Meet Primary Efficacy Endpoints
- Zosano Pharma, Inc. to Provide Pipeline Updates at the 2009 AAPS Annual Meeting
- UCL (University College London) Liver Failure Group Present Two Studies on a Novel Treatment Option (OCR-002) for Complications of Hyperammonemia in Liver Failure at the 60th Annual AASLD Meeting
- Twice Daily Oral Medication Shows Promise in Treating Patients with Hepatitis C
- YM BioSciences reports positive nimotuzumab four-year survival data presented at ASTRO 2009
- Bristol-Myers Squibb and ZymoGenetics Present Final Phase 1b Results for PEG-Interferon Lambda in Hepatitis C
- Enzo Biochem Reports on Favorable Clinical Trial of EGS21 for Treatment of Non-Alcoholic Steatohepatitis
- Gilead Announces Long-Term Data from Two Pivotal Phase III Studies Evaluating Viread For Chronic Hepatitis B
- BARACLUDE (entecavir) Demonstrated Greater Antiviral Efficacy Compared to Adefovir in New Study of Chronic Hepatitis B Patients with Evidence of Decompensated Cirrhosis
- FibroGen Announces New Research in Anti-CTGF and HIF-PHI Therapeutic Development Programs in Kidney Disease
- NovaBay's Aganocides Show Penetration and Efficacy in a Pre-Clinical Infected Human Nail Model of Onychomycosis
- Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C
- Mayo Clinic Proceedings Publishes Study of NUVIGIL in Patients with Shift Work Disorder
November 3, 2009
- Sanofi Pasteur Presents Safety Data on Menactra Vaccine Given to Infants at Infectious Disease Society Meeting
- Study Finds Lack of Diffusible VEGF Growth Factor Can Cause Retinal Defects Similar to Dry Macular Degeneration
- Idera Pharmaceuticals Presents Preclinical Data on IMO-2125, its Lead Drug Candidate for Chronic Hepatitis C Virus Infection, at Liver Meeting 2009
- MagForce Nanotechnologies AG reaches primary study endpoint in pivotal glioblastoma study
- Ironwood and Forest Announce Positive Linaclotide Results from Two Pivotal Phase 3 Trials in Patients with Chronic Constipation
- SCYNEXIS' SCY-635 Demonstrates Positive Antiviral Activity in Combination with Approved and Investigational Anti-HCV Agents
- ARIAD's AP24534 Featured in Cancer Cell Publication as a Potential First-in-Class Pan BCR-ABL Inhibitor
- INFORM-1 Results: Robust Antiviral Suppression Achieved with Combination of Nucleoside Analog Polymerase Inhibitor RG7128 and Protease Inhibitor RG7227
- Data for EntreMed's ENMD-2076 to Be Presented at the Upcoming AACR-NCI-EORTC Conference
November 4, 2009
- New Phase IIa data on TMC435 in patients with hepatitis C presented at the ongoing AASLD - meeting
- Long-term Outcomes Data Validates the Utility of PROSTASCINT in Guiding Targeted Prostate Cancer Treatment and Predicting Disease Free Survival
- Promedior Announces Publication of Preclinical Studies in Science Translational Medicine Demonstrating that hSAP Inhibits Kidney Fibrosis
- Aeolus Pharmaceuticals' AEOL 10150 Protects Lungs Against Chlorine Gas Exposure in Animal Studies
- New Data on Attention in Children with ADHD
- Principal Investigators Association Launches Free Weekly Ezine to Advise Scientists in All Fields of Research on Their Administrative Challenges
- Concerta in the Classroom: New Data on Attention in Children With ADHD
- Thirteen Abstracts Featuring Exelixis Compounds Accepted for Presentation at the 2009 AACR-NCI-EORTC International Conference
November 5, 2009
- Alnylam Presents New Pre-Clinical Data on RNAi Therapeutics at Oligonucleotides Therapeutics Society (OTS) Meeting
- Significantly More Smokers With Mild-To-Moderate COPD Quit Smoking Using CHANTIX/CHAMPIX (Varenicline) Compared With Placebo
- Chelation Therapy Drug Found Safe and Beneficial for Children With Autism
- Short-Term Hormone Therapy Added to Radiation Increases Survival for Medium-Risk, But Not Low-Risk, Prostate Cancer Patients
- BioVex Announces Publication of Phase 2 Melanoma Results With OncoVEX (GM-CSF) in the Journal of Clinical Oncology
- Ocera Therapeutics Presents Clinical Data Demonstrating AST-120 Relieves Pruritus in Patients with Liver Cirrhosis at the 60th Annual AASLD Meeting
- Amgen Announces Overall Survival Results for Vectibix in First-Line Metastatic Colorectal Cancer
- Approved Lymphoma Drug Shows Promise in Early Tests Against Bone Cancer
- M. D. Anderson News Release: Early Stage, HER2 Positive Breast Cancer Patients at Increased Risk of Recurrence
- Pharmaceutical Press empowers users with enhanced MedicinesComplete
- New Safety Data on Menactra for Infants
- Valeant Pharmaceuticals Highlights Taribavirin Phase IIb End of Study Data Presentation at American Association for the Study of Liver Disease (AASLD) Annual Meeting
- Journal Cancer Publishes Pivotal Study of TREANDA in Patients with in Relapsed Indolent NHL
- New Data on Bendamustine Offers Hope to Non-Hodgkin's Lymphoma Patients Resistant to Standard Therapy
November 6, 2009
- ZIOPHARM Presents Positive Palifosfamide Sarcoma Randomized Phase II Interim Data at Annual Meeting of the Connective Tissue Oncology Society
- Oncolytics Biotech Inc. Collaborators Present Positive Phase II Sarcoma Trial Results at CTOS Annual Meeting
- Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting
- NexBio Publishes Two Articles Showing DAS181 (Fludase) Potently Inhibits Pandemic Influenza A(H1N1) and NAI-Resistant Influenza Viruses
- Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox
November 9, 2009
- BrainStorm Stem Cell Therapy Treatment Shown To Be More Effective Than Other Current Potential Stem Cell Treatments
- ISTA Pharmaceuticals Highlights Bepreve Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
- Pandemic 2009 Influenza Update: Pandemrix data on co-administration with annual seasonal influenza vaccine (Fluarix)
- Æterna Zentaris: Scientific Article Supports Perifosine?s Development in Kidney Cancer
- Halozyme Study Results Demonstrate Significantly Less Absorption Variability for Insulin Lispro Administered with PH20 Enzyme
- Zosano Pharma, Inc. Announces Publication of Positive Phase 2 Study of Its ZP-PTH Patch for Osteoporosis Therapy
- DX-88 (ecallantide) Demonstrated Relief of Symptoms in Hereditary Angioedema Acute Attacks in All Attack Locations
- CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
- OssulinTM, a Novel Oral Insulin Product, Shows Promising Bioavailability for Advancing Diabetes Therapy
- NexBio Presents Data Showing Anti-Asthma Activity of DAS181 (Fludase(R)*) at ACAAI 2009
- SuperGen Presentations at AACR-NCI-EORTC
November 10, 2009
- ImmunoGen, Inc. Announces Presentations at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Roche reports positive Phase II results with potential first-in-class treatment for the negative symptoms of schizophrenia
- Avanir Pharmaceuticals Announces Zenvia Safety and Efficacy Data from Star Trial Open Label Extension
- Cytos Biotechnology updates on the development of the hypertension vaccine CYT006-AngQb
- Labopharm's novel trazodone formulation subject of publication in peer-reviewed medical journal
- Independent Study Utilizing Cyclic Levulan PDT Finds 95 Percent Reduction in New Squamous Cell Carcinoma Lesions in Solid Organ Transplant Recipients Over a 2-Year Period
November 11, 2009
- Crinone 8% (progesterone vaginal gel) As Effective as Hormone Injections During IVF? Is Medscape's ?Top News? from The ASRM 65th Annual Meeting
- More Than 200 Abstracts Evaluating Celgene Products across a Range of Indications to Be Presented at the 51st American Society of Hematology Meeting
- Geron Collaborators Publish Data on hESC-Derived Glial Progenitor Cell Therapy in Cervical Spinal Cord Injury
- DUSA's Levulan PDT found to reduce squamous cell carcinomas by 95% in solid organ transplant recipients
- BioClinica to Host Medical Imaging Symposium for Rheumatoid Arthritis Clinical Trials on November 18, 2009
- NanoViricides, Inc. to Present Anti-Influenza Drug Candidate FluCide Studies at the Influenza Congress 2009
- Avanir Pharmaceuticals Announces Zenvia Safety and Efficacy Data from Star Trial Open Label Extension
- Drugs to Treat Anemia in Cancer Patients Linked to Thromboembolism
- Video: Sanofi Pasteur Announces Final Results of U.S. Clinical Trials of Influenza A (H1N1) Vaccine in Adults and Children
- Viron to Present Data from Phase II Trial at American Heart Association Conference
- Landmark Study in The Lancet Oncology Shows Capecitabine (Xeloda) Combination Therapy Reduces Early Breast Cancer Recurrence
November 12, 2009
- Mersana Therapeutics Publishes Review Article Detailing Advantages of its Lead Cancer Compound in Journal of Advanced Drug Delivery Reviews
- Shire Reports Findings From an Analysis Examining Emotional Lability in Children With ADHD Taking Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII
- BioAlliance Pharma Presents Results for Its New Oral Chemotherapy Nanoparticle Innovation at the AAPS Annual Meeting in Los Angeles, November 8 to 12, 2009
- Holllis-Eden to Present Interim Data From Its Phase I/II Clinical Studies of Apoptone (HE3235) at Molecular Targets and Cancer Therapeutics Conference
- Euro RSCG Life Presents Proprietary Survey Insights at Food and Drug Administration Hearing on Pharmaceutical Promotion via Online and Social Media
- Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
- Lexicon Announces Positive Phase 2 Results of LX1031 in Non-Constipating Irritable Bowel Syndrome
November 13, 2009
- BioTime CEO Dr. Michael West to Present at Stem Cells USA & Regenerative Medicine Congress 2009
- Larry Weber: ?Current FDA Regulations Reflect a Pre-Web Communications Paradigm?
- Cleviprex Results Reported From Study in Patients With Intracerebral Hemorrhage
November 16, 2009
- Poniard Pharmaceuticals Announces Pivotal Phase 3 SPEAR Trial of Picoplatin in Small Cell Lung Cancer Did Not Meet Primary Endpoint
- Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid Dependence
- Genta Announces Results of AGENDA Phase 3 Trial of Genasense in Patients with Advanced Melanoma
- Addex ADX10059 Monotherapy is Effective on GERD Symptoms in Phase IIb Clinical Trial
- Gentium Announces Presentation of Defibrotide Clinical Data at the American Society of Hematology Annual Meeting
- BioInvent and ThromboGenics Complete Phase I Patient Trial of Anti-PlGF Cancer Therapeutic TB-403 in Patients with Advanced Solid Tumours
November 17, 2009
- Novartis Influenza A(H1N1) 2009 vaccine US interim data show lower doses of antigen may suffice to generate a protective immune response against A(H1N1)
- NicOx - NCX 6560 meets primary and secondary objectives in first-in-man study
- The Medicines Company Announces Positive Phase III Data in Two Late-Breakers at AHA and in NEJM
- Ticagrelor (BRILINTA) Demonstrated Greater Efficacy Over Clopidogrel in the Most Urgent Clinical Setting
- Data from Mipomersen Phase 3 Trial in hoFH Patients Presented at AHA
- Shire Announces Publication of Open-Label Study on Coadministration of INTUNIV (guanfacine) Extended-Release Tablets with Stimulants
- Oncolytics Biotech Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting
- American Heart Association Late Breaking Clinical Trial Report: Treatment for Iron Deficiency Improves Symptoms, Functional Capacity and Quality of Life in Chronic Heart Failure Patients
- Poniard Pharmaceuticals Announces Updated Positive Clinical Data from Phase 2 Trial of Picoplatin in Colorectal Cancer and New Phase 1 Cardiac Safety Trial Results
- AVEO's Triple VEGF Receptor Inhibitor Tivozanib in Combination with mTOR Inhibitor Demonstrates Anti-tumor Activity and Tolerability in Advanced Kidney Cancer; Preliminary Results Presented at AACR-NCI-EORTC Meeting
- ImmunoGen, Inc. Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma
- Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor XL147 (SAR245408) in Combination with Paclitaxel and Carboplatin at the AACR-NCI-EORTC Conference
- Interim Phase 2 Survival Data for PV-10 Will Be Presented by Professor John F. Thompson, MD, on November 21, 2009
- Merck's Investigational Anacetrapib Phase IIb Study Results Presented at American Heart Association Annual Scientific Sessions
- NeoPharm Presents the Phase I Data for Patients with Metastatic Solid Tumors
- Higher Dose of Merck's Cozaar (losartan potassium tablets) Significantly Reduced Deaths and Hospitalizations Due to Heart Failure In Investigational Study
- Pluristem Therapeutics Announces Three Month Follow-Up Data from the First Patient to Receive PLX-PAD
- Aegerion Pharmaceuticals Announces Additional Lomitapide (AEGR-733) Phase III Data Demonstrates Significant Lowering of LDL Cholesterol with Promising Safety Profile
- BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction
- Semafore Pharmaceuticals Announces Phase I Data Presentation Highlighting Novel PI3K Pathway Inhibitor at 51st ASH Annual Meeting
- American Heart Association Late Breaking Clinical Trial Report: High Dose of Angiotensin Receptor Blockers Effective in Heart Failure Patients
- YM Biosciences Reports Cyt997 Oral Vascular Disrupting Agent Results Presented At AACR-NCI-EORTC Meeting
November 18, 2009
- Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
- Alnylam Presents New Pre-clinical Data on ALN-VSP, an RNAi Therapeutic for the Treatment of Liver Cancer
- Results From Phase 2b Study on Atrial Fibrillation Agent Reviewed at American Heart Association
- ImmunoGen Announces Encouraging Clinical Data with Its IMGN901 Compound in the Treatment of Merkel Cell Carcinoma
- Genzyme Announces Results of Phase 2/3 Trial of Advanced Phosphate Binder
- Viron reports positive Phase II data in Acute Coronary Syndromes (ACS) patients
- Threshold Pharmaceuticals Presents Interim Prostate Cancer Data From Early Stage Trials of TH-302
- Zydena is Efficacious in Once Daily Dosing for Erectile Dysfunction/Positive BPH Results
- Cardiovascular Outcomes with Ezetimibe and Simvastatin Similar to Statin Alone, Claims Data Suggest
- Exelixis Reports Encouraging Phase 1 Data for the PI3K Inhibitor Xl147 (SAR245408) in Combination with Erlotinib at the AACR-NCI-EORTC Conference
- Results From Two Phase II Trials Add to Understanding of Ticagrelor (BRILINTA(TM)) and How it Works in the Body
- Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
- Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS
- Synta Presents New Data on Mechanism of Action of Elesclomol at AACR-NCI-EORTC Conference on Molecular Targets and Cancer Therapeutics
- Synta Presents Preclinical Data on Next Generation Hsp90 Inhibitor, STA-9090
November 19, 2009
- Geron Presents Interim Clinical Data on Its Telomerase Inhibitor Drug at AACR-NCI-EORTC
- Medivir: Epiphany Biosciences Announces Positive Results from Its Phase 2b Trial in Shingles
- Basilea presents new research data on oncology drug candidate BAL27862 at international cancer conference
- VIVUS Announces Positive Results From Phase 3 Study of Avanafil in Erectile Dysfunction; Data Demonstrate Robust Efficacy, Favorable Side-Effect Profile
- ImmuPharma announces Positive Ph2b Lupuzor trial results
- Epiphany Announces Positive Results from Its Phase 2b Trial in Shingles.
- Positive Results from Chronic Study with Bayer ?s Rivaroxaban Will be Presented As a Late Breaker at ASH 2009
- Notice of YM BioSciences Annual Meeting of Shareholders
- NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company
- Spherix Announces Results of Annual Shareholders Meeting
- OSI Pharmaceuticals to Webcast its R&D Analyst Day on Thursday, December 3rd
- Military Study Shows Prevention of Novel A/H1N1 Virus Infection is Vaccine-Type and Age-Dependent
- Interphase Systems Launches Managed IT Solution for BioPharma Companies
- Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites
- TGaS Advisors Summit: "Best Days are Ahead"
- ScinoPharm Announces SafeBridge Potent Compound Safety Certification
November 20, 2009
- Inovio Biomedical Universal Flu Vaccines Demonstrate Broadly Protective Immune Responses Against Multiple Seasonal & Pandemic Influenza Viruses in Pre-Clinical Studies
- Ligand Presents New Preclinical Data on its Lead SARM Molecule LGD-4033 at the Gerontological Society of America Annual Meeting
- Genasense Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma
November 22, 2009
- ImmuPharma PLC: Encouraging Final Phase IIb Results Seen with LUPUZOR in Systemic Lupus Erythematosus
- Sciele Pharma, a Shionogi Company, Presents Pivotal Study for PSD502 ? The First Potential Treatment for Premature Ejaculation ? At the Sexual Medicine Society of North America (SMSNA)
- Ironwood Pharmaceuticals Files Registration Statement for Initial Public Offering
- Pluristem Therapeutics Presents Three Month Follow-Up Data from First Patient to Receive Placental Derived PLX-PAD at Two Meetings in Germany and France
- Enzon Presents Data at 2009 EORTC Meeting
- Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
- NUCRYST Announces Special Meeting of Shareholders
- Circassia Announces Successful Results From Phase II Clinical Study of ToleroMune Cat Allergy Therapy
- Cell Therapeutics Wins Federal Appeal to Pursue $22.8 Million Claim Against The Lash Group
- Ohio Mother Charges Yaz Birth Control Drug Caused Life-Threatening Blood Clot
- Karolinska Development and EIF Start Landmark Co-Investment Fund for Life Science Innovation
- KineMed Receives an Investigator-Initiated Study Grant to Further Explore Mechanism(s) of Action Associated with Welchol (colesevelam HCl) in Type 2 Diabetes Mellitus
- BioCryst Announces Pricing of Public Offering of Common Stock
November 23, 2009
- NanoViricides Presents FluCide Animal Study Data at Influenza Congress - Now Improved Substantially and Vastly Superior to Current Treatment
- ARIAD to Present Data on Pan-BCR-ABL Inhibitor AP24534 at 51st American Society of Hematology Meeting
- Interim Phase 2 Survival Data for PV-10 Shows Markedly Longer Overall and Disease Specific Survival for Subjects Responsive to PV-10
- Genasense® Given as High-Dose IV Infusion with Chemotherapy Shows Promising Activity in Advanced Melanoma
- Merck KGaA to Expand Research and Development Presence in China
- Pronova BioPharma ASA (NO) - Pronova BioPharma ASA presented at "Aksjedagen Norge" 2009
- Ception Therapeutics and Cephalon Provide Initial Results of a Phase IIb/III Study of CINQUIL in Pediatric Eosinophilic Esophagitis
- Isis Pharmaceuticals (Nasdaq: ISIS) Letter to Shareholders
- Lexicon to Present Positive Top-Line Phase 2 Results for LX1031 in Non-Constipating Irritable Bowel Syndrome at GASTRO 2009
- Biotec Pharmacon ASA (NO) - Phase III Results With SBG for Diabetic Foot Ulcer Not Positive
- Chiesi Is Top Italian Pharmaceutical Group for Investment In Research
- Nymox Releases Positive New Clinical Trial Data on Durability of Benefits for Early Responders to Company?s BPH Drug NX-1207
- Genfit: Extremely Promising Gft505 Results In Phase Ii
- NexMed, Inc. to Acquire Bio-Quant, Inc.
- Nereus Pharmaceuticals Presents Positive Interim Data from the ADVANCE Study, a Randomized Phase 2 Clinical Trial of Plinabulin (NPI-2358) in Non-Small Cell Lung Cancer at the 2009 EORTC-NCI-AACR Conference
November 24, 2009
- Addex Pharmaceuticals (CH) - Addex ADX48621 Positive Primate Parkinson's Data
- CombinatoRx Oncology Programs to Be Highlighted at ASH 2009
- AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer
- Caldolor (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients
- Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain
November 25, 2009
- Biovitrum (SE) - Kiobrina shows positive phase II results in preterm infants
- Sucampo Announces Lubiprostone Data Presented at GASTRO 2009 UEGF/WCOG
- Gloucester Pharmaceuticals to Present Positive Results from Multiple Studies of ISTODAX at the ASH Annual Meeting
